Pēdējā atjaunošana :
19/11/2024
vēzis narkotiku   Fludarabine phosphate  
Injekcija
Šķīduma stabilitāte Maisījuma stabilitāte Stabilitāti ietekmējoši faktori Saderība Levadīšanas veids Literatūras saraksts pdf
   Ķīmiskā uzbūve   

Oriģinālais nosaukums   Oriģinālais nosaukums     

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Acetaflur Meksika
Asoleudox Meksika
Beneflur Meksika, Spānija
Fludabin Peru
Fludacel Indija, Peru
Fludakebir Peru
Fludalym Turcija
Fludara Amerikas Savienotās Valstis, Austrija, Beļģija, Čīle, Dānija, Ēģipte, Francija, Holande, Indija, Irāna, Īrija, Itālija, Jaunzēlande, Kolumbija, Lielbritānija, Luksemburga, Malaizija, Polija, Portugāle, Rumānija, Saūda Arābija, Somija, Šveice, Ungārija, Vācija, Venecuēla, Zviedrija
Fludarabin Islande, Itālija, Norvēģija, Šveice, Zviedrija
Fludarabina Argentīna, Kolumbija, Peru, Rumānija, Spānija
Fludarabine Amerikas Savienotās Valstis, Beļģija, Irāna, Jaunzēlande, Kanāda, Norvēģija, Šveice
Fludarin Indija
Fludarosa Argentīna
Forclina Peru
Ludabina Čīle, Kolumbija
Mepredin Peru
Naprobin Indija
Neoflubin Irāna
Literatūras saraksts   Injekcija   Literatūras saraksts : Fludarabine phosphate  
tips publicēšana
3 Žurnāls Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Žurnāls Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Žurnāls Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Žurnāls Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Žurnāls Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Žurnāls Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Žurnāls Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Žurnāls Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Žurnāls Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
492 Žurnāls Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Žurnāls Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 Žurnāls Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Žurnāls Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
2344 Laboratorija Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3306 Žurnāls Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2.
3595 Laboratorija Aciclovir - Summary of Product Characteristics
Hospira 2009
3604 Laboratorija Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3637 Laboratorija Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3644 Laboratorija Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3670 Žurnāls Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3838 Laboratorija Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4398 Žurnāls Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020

  Mentions Légales